-
1
-
-
33845491265
-
Medical progress: Acromegaly
-
Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355: 2558-2573.
-
(2006)
N Engl J Med
, vol.355
, pp. 2558-2573
-
-
Melmed, S.1
-
3
-
-
49249113074
-
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
-
Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93: 2957-2968.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 2957-2968
-
-
Murray, R.D.1
Melmed, S.2
-
5
-
-
74749095613
-
Reference intervals of serum insulin-like growth factor-I in adult Japanese population: Calculated with LMS methods
-
in Japanese
-
Shimatsu A, Chihara K, Hizuka N, Teramoto A, Tanaka T, Tatsumi K, Tachibana K, Katsumata N, Yokoya S, Fujieda K (2007) Reference intervals of serum insulin-like growth factor-I in adult Japanese population: calculated with LMS methods. Horumon To Rinsho (Clinical endocrinology) 55: 393-399 (in Japanese).
-
(2007)
Horumon To Rinsho (Clinical endocrinology)
, vol.55
, pp. 393-399
-
-
Shimatsu, A.1
Chihara, K.2
Hizuka, N.3
Teramoto, A.4
Tanaka, T.5
Tatsumi, K.6
Tachibana, K.7
Katsumata, N.8
Yokoya, S.9
Fujieda, K.10
-
7
-
-
49649113676
-
High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels
-
Schneider HJ, Sievers C, Saller B, Wittchen HU, Stalla GK (2008) High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 69: 432-435.
-
(2008)
Clin Endocrinol (Oxf)
, vol.69
, pp. 432-435
-
-
Schneider, H.J.1
Sievers, C.2
Saller, B.3
Wittchen, H.U.4
Stalla, G.K.5
-
8
-
-
33845489470
-
High prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium
-
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91: 4769-4775.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 4769-4775
-
-
Daly, A.F.1
Rixhon, M.2
Adam, C.3
Dempegioti, A.4
Tichomirowa, M.A.5
Beckers, A.6
-
9
-
-
38149140111
-
Mortality in acromegaly: A metaanalysis
-
Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 93: 61-67.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 61-67
-
-
Dekkers, O.M.1
Biermasz, N.R.2
Pereira, A.M.3
Romijn, J.A.4
Vandenbroucke, J.P.5
-
10
-
-
18544363593
-
Guidelines for acromegaly management
-
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87: 4054-4058.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 4054-4058
-
-
Melmed, S.1
Casanueva, F.F.2
Cavagnini, F.3
Chanson, P.4
Frohman, L.5
Grossman, A.6
Ho, K.7
Kleinberg, D.8
Lamberts, S.9
Laws, E.10
Lombardi, G.11
Vance, M.L.12
Werder, K.V.13
Wass, J.14
Giustina, A.15
-
11
-
-
0030740018
-
Cabergoline treatment of acromegaly: A preliminary dose finding study
-
Jackson SN, Fowler J, Howlett TA (1997) Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 46: 745-749.
-
(1997)
Clin Endocrinol (Oxf)
, vol.46
, pp. 745-749
-
-
Jackson, S.N.1
Fowler, J.2
Howlett, T.A.3
-
12
-
-
85137137537
-
-
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177.
-
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171-1177.
-
-
-
-
13
-
-
0031812096
-
Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
-
Landolt AM, Haller D, Lomax N, Scheib S, Schubiger O, Siegfried J, Wellis G (1998) Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 88: 1002-1008.
-
(1998)
J Neurosurg
, vol.88
, pp. 1002-1008
-
-
Landolt, A.M.1
Haller, D.2
Lomax, N.3
Scheib, S.4
Schubiger, O.5
Siegfried, J.6
Wellis, G.7
-
14
-
-
33645009542
-
Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: Predictors of tumor shrinkage
-
Oshino S, Saitoh Y, Kasayama S, Arita N, Ohnishi T, Kohara H, Izumoto S, Yoshimine T (2006) Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage. Endocr J 53: 125-132.
-
(2006)
Endocr J
, vol.53
, pp. 125-132
-
-
Oshino, S.1
Saitoh, Y.2
Kasayama, S.3
Arita, N.4
Ohnishi, T.5
Kohara, H.6
Izumoto, S.7
Yoshimine, T.8
-
15
-
-
36549040940
-
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly
-
Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157: 579-587.
-
(2007)
Eur J Endocrinol
, vol.157
, pp. 579-587
-
-
Colao, A.1
Pivonello, R.2
Auriemma, R.S.3
Galdiero, M.4
Savastano, S.5
Lombardi, G.6
-
17
-
-
34347380169
-
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
-
Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66: 859-868.
-
(2007)
Clin Endocrinol (Oxf)
, vol.66
, pp. 859-868
-
-
Mercado, M.1
Borges, F.2
Bouterfa, H.3
Chang, T.C.4
Chervin, A.5
Farrall, A.J.6
Patocs, A.7
Petersenn, S.8
Podoba, J.9
Safari, M.10
Wardlaw, J.11
-
18
-
-
45149134343
-
No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly
-
Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, Weissman NJ (2008) No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab 93: 2243-2248.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 2243-2248
-
-
Colao, A.1
Marek, J.2
Goth, M.I.3
Caron, P.4
Kuhn, J.M.5
Minuto, F.M.6
Weissman, N.J.7
-
19
-
-
20844461864
-
Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: The relationship with endogenous srif activity and response to octreotide
-
Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 51: 227-236.
-
(2004)
Endocr J
, vol.51
, pp. 227-236
-
-
Park, C.1
Yang, I.2
Woo, J.3
Kim, S.4
Kim, J.5
Kim, Y.6
Sohn, S.7
Kim, E.8
Lee, M.9
Park, H.10
Jung, J.11
Park, S.12
-
20
-
-
59749098584
-
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: Results of a 5-year observational, open, prospective study
-
Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94: 528-537.
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 528-537
-
-
Colao, A.1
Auriemma, R.S.2
Galdiero, M.3
Cappabianca, P.4
Cavallo, L.M.5
Esposito, F.6
Grasso, L.F.7
Lombardi, G.8
Pivonello, R.9
-
21
-
-
33750039351
-
Medical treatment of acromegaly: Comorbidities and their reversibility by somatostatin analogs
-
Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A (2006) Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology 83: 249-257.
-
(2006)
Neuroendocrinology
, vol.83
, pp. 249-257
-
-
Tolis, G.1
Angelopoulos, N.G.2
Katounda, E.3
Rombopoulos, G.4
Kaltzidou, V.5
Kaltsas, D.6
Protonotariou, A.7
Lytras, A.8
-
22
-
-
0023023461
-
Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly
-
Horikawa R, Takano K, Hizuka N, Asakawa K, Shibasaki T, Masuda A, Shizume K (1986) Effect of a single administration of somatostatin analogue (SMS 201-995) on GH, TSH and insulin secretion in patients with acromegaly. Endocrinol Jpn 33: 743-749.
-
(1986)
Endocrinol Jpn
, vol.33
, pp. 743-749
-
-
Horikawa, R.1
Takano, K.2
Hizuka, N.3
Asakawa, K.4
Shibasaki, T.5
Masuda, A.6
Shizume, K.7
-
23
-
-
0029586762
-
Short-term effects of octreotide on glucose tolerance in patients with acromegaly
-
Sato K, Takamatsu K, Hashimoto K (1995) Short-term effects of octreotide on glucose tolerance in patients with acromegaly. Endocr J 42: 739-745.
-
(1995)
Endocr J
, vol.42
, pp. 739-745
-
-
Sato, K.1
Takamatsu, K.2
Hashimoto, K.3
|